Literature DB >> 1896249

The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants.

S D Revak1, T A Merritt, M Hallman, G Heldt, R J La Polla, K Hoey, R A Houghten, C G Cochrane.   

Abstract

Synthetic pulmonary surfactants consisting of mixtures of phospholipids with synthetic peptides based on the amino acid sequence of human surfactant apoprotein SP-B were prepared. These surfactants were analyzed for their ability to lower surface tension on a pulsating bubble surfactometer and for their capacity to improve lung compliance and increase alveolar expansion in a fetal rabbit model of surfactant deficiency. The data demonstrate that several peptides, ranging from 17 to 45 residues in length, matching the carboxy-terminal sequence of the SP-B protein, when appropriately recombined with the phospholipid dipalmitoylphosphatidylcholine and phosphatidylglycerol (3:1), are capable of producing a synthetic surfactant with biophysical and biologic activity approaching that of human surfactant derived from amniotic fluid.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896249     DOI: 10.1203/00006450-199105010-00010

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  22 in total

1.  Penetration depth of surfactant peptide KL4 into membranes is determined by fatty acid saturation.

Authors:  Vijay C Antharam; Douglas W Elliott; Frank D Mills; R Suzanne Farver; Edward Sternin; Joanna R Long
Journal:  Biophys J       Date:  2009-05-20       Impact factor: 4.033

2.  Effects of a cationic and hydrophobic peptide, KL4, on model lung surfactant lipid monolayers.

Authors:  J Ma; S Koppenol; H Yu; G Zografi
Journal:  Biophys J       Date:  1998-04       Impact factor: 4.033

3.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

4.  Close mimicry of lung surfactant protein B by "clicked" dimers of helical, cationic peptoids.

Authors:  Michelle T Dohm; Shannon L Seurynck-Servoss; Jiwon Seo; Ronald N Zuckermann; Annelise E Barron
Journal:  Biopolymers       Date:  2009       Impact factor: 2.505

Review 5.  The fate of exogenous surfactant in neonates with respiratory distress syndrome.

Authors:  M Hallman; T A Merritt; K Bry
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

6.  Effects of the lung surfactant protein B construct Mini-B on lipid bilayer order and topography.

Authors:  Dharamaraju Palleboina; Alan J Waring; Robert H Notter; Valerie Booth; Michael Morrow
Journal:  Eur Biophys J       Date:  2012-08-19       Impact factor: 1.733

7.  Reduction of the surface-tension-lowering ability of surfactant after exposure to hypochlorous acid.

Authors:  T A Merritt; J D Amirkhanian; H Helbock; B Halliwell; C E Cross
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

8.  Interactions of the C-terminus of lung surfactant protein B with lipid bilayers are modulated by acyl chain saturation.

Authors:  Vijay C Antharam; R Suzanne Farver; Anna Kuznetsova; Katherine H Sippel; Frank D Mills; Douglas W Elliott; Edward Sternin; Joanna R Long
Journal:  Biochim Biophys Acta       Date:  2008-07-25

9.  The surfactant peptide KL4 sequence is inserted with a transmembrane orientation into the endoplasmic reticulum membrane.

Authors:  Luis Martínez-Gil; Jesús Pérez-Gil; Ismael Mingarro
Journal:  Biophys J       Date:  2008-07-11       Impact factor: 4.033

10.  Critical structural and functional roles for the N-terminal insertion sequence in surfactant protein B analogs.

Authors:  Frans J Walther; Alan J Waring; Jose M Hernandez-Juviel; Larry M Gordon; Zhengdong Wang; Chun-Ling Jung; Piotr Ruchala; Andrew P Clark; Wesley M Smith; Shantanu Sharma; Robert H Notter
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.